Gilead Sciences GILD today announced results from two
Phase 2 studies evaluating an all-oral treatment regimen of the
investigational once-daily nucleotide analogue sofosbuvir plus ribavirin
(RBV) for both the prevention and treatment of recurrent chronic
hepatitis C virus (HCV) infection among patients who undergo liver
transplantation. The findings will be presented this week at the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (The Liver Meeting 2013) in Washington, D.C.
HCV infection is the most common cause of liver transplantation in the
United States and Europe. Recurrence of HCV infection is universal among
patients with active disease at the time of transplantation and up to 50
percent develop cirrhosis
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in